Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study with Peluntamig (PT217) Followed by a Key ChemotherapY And/or Checkpoint Inhibitor ComBination in Patients with NeuRoendocrIne Carcinomas That Are Known to Be DLL3 ExpressinG CancErs (SKYBRIDGE)

Next Previous
Trial Profile

An Open-label, Multicenter, Dose Escalation, and Dose Expansion Phase 1/2 Study with Peluntamig (PT217) Followed by a Key ChemotherapY And/or Checkpoint Inhibitor ComBination in Patients with NeuRoendocrIne Carcinomas That Are Known to Be DLL3 ExpressinG CancErs (SKYBRIDGE)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; PT-217 (Primary)
  • Indications Gastrointestinal cancer; Lung cancer; Neuroendocrine carcinoma; Pancreatic cancer; Prostate cancer; Small cell lung cancer
  • Focus Adverse reactions; First in man
  • Acronyms the SKYBRIDGE Study
  • Sponsors Phanes Therapeutics

Most Recent Events

  • 08 May 2025 According to Phanes Therapeutics media release, the company has entered into a clinical supply agreement with Roche to study PT217 in combination with Roches anti-PD-L1 therapy, atezolizumab, in patients with small cell lung cancer (SCLC), large cell neuroendocrine carcinoma of the lung (LCNEC) and extrapulmonary neuroendocrine carcinomas (EP-NECs).
  • 05 May 2025 According to Phanes Therapeutics media release, the first patient has been dosed in the clinical study of peluntamig in combination with atezolizumab
  • 19 Feb 2025 According to Phanes Therapeutics media release, company announces the first patient with small cell lung cancer dosed in a trial of peluntamig combined with chemotherapy in the SKYBRIDGE study.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top